The FY2025 (Dec) proxy of Trevi Therapeutics names 18 peer companies for pay. Among Trevi Therapeutics and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 7.
6th highest of 7in Trevi Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$1.4M$10.0M
1st highest of 7in Trevi Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$17$649
Pay peer group, FY2025 (Dec) proxy
| Disc Medicine | ||
| Spyre Therapeutics | ||
| Anaptysbio | ||
| Celldex Therapeutics | ||
| Savara | ||
| Arbutus Biopharma | ||
| Anavex Life Sciences | Not disclosed | Not disclosed |
| Astria Therapeutics | Not disclosed | Not disclosed |
| Belite Bio | Not disclosed | Not disclosed |
| Centessa Pharmaceuticals | Not disclosed | Not disclosed |
| Dianthus Therapeutics | Not disclosed | Not disclosed |
| Edgewise Therapeutics | Not disclosed | Not disclosed |
| Janux Therapeutics | Not disclosed | Not disclosed |
| Kodiak Sciences | Not disclosed | Not disclosed |
| Mineralys Therapeutics | Not disclosed | Not disclosed |
| Rapport Therapeutics | Not disclosed | Not disclosed |
| Rezolute | Not disclosed | Not disclosed |
| Upstream Bio | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.